Coherus BioSciences, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 91.52 million compared to USD 45.35 million a year ago. Net loss was USD 79.65 million compared to USD 58.87 million a year ago. Basic loss per share from continuing operations was USD 0.71 compared to USD 0.76 a year ago.
For the full year, sales was USD 257.24 million compared to USD 211.04 million a year ago. Net loss was USD 237.89 million compared to USD 291.75 million a year ago. Basic loss per share from continuing operations was USD 2.53 compared to USD 3.76 a year ago.